Loading
Life sciences · Journal article
Lung India · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background: KRAS mutated metastatic non-small cell lung cancer (NSCLC) is characterized by clinical and genomic heterogeneity. There is paucity of data on this subtype from low- and middle- income countries (LMICs), where emerging therapeutic options are of limited accessibility. Methods: We conducted a retrospective study at Regional Cancer Centre, Kerala, India between June 2021 and June 2025. 220 metastatic NSCLC cases underwent NGS; 57/220 (26%) were KRAS mutated and formed the descriptive cohort. After exclusions, 47 were evaluable for response and survival, analysed using Kaplan Meier and log rank tests (two-sided P ≤ 0.05). Results: Median age was 61 years; 73% were men; 63% had a smoking history. The most KRAS mutations were G12C (37%), G12D (19%), G12A (16%), and G12V (12%). Co-mutations occurred in 53% ( TP53 35%, PIK3CA 11%). 28% patients were PD-L1 positive. First-line therapy was predominantly platinum doublet (83%); with added bevacizumab in 16% and an immune checkpoint inhibitor (ICI) in 7%. At a median follow-up of 19.9 months, median progression-free survival (PFS) was 9.6 months (95% CI: 7.47–13.23), and median overall survival (OS) was 12.07 months (95% CI: 9.10–16.33). G12C mutation conferred improved OS whereas, Eastern Co-operative Oncology Group Performance Status (ECOG PS) ≥2 and TP53 co-mutation predicted inferior OS. Anti-vascular endothelial growth factor (VEGF) exposure showed a trend towards improved OS. Conclusions: In this South Indian cohort, KRAS mutations were heterogeneous, G12C-predominant. Overall survival was modest, reflecting limited access to immunotherapy and KRAS inhibitors. G12C subtype had improved outcomes while TP53 co-mutation had poorer outcomes. These findings support broader molecular testing, better therapy access, and prospective validation in LMICs.